If you haven`t bought SRPT here:
Then you need to know that there is a Massive catalyst coming!
Sarepta Therapeutics is going to announce Duchenne muscular dystrophy Phase 3 data for its SRP-9001-301 - (EMBARK) by mid November.
This week institutions bought calls worth more than $10Mil that SRPT Sarepta Therapeutics will trade above $135 by November 17.
Some...
Looking at the SRPT Sarepta Therapeutics options chain, i would buy the $125 calls with
2023-2-17 expiration date for about
$7.10 premium.
Looking forward to read your opinion about it.
$SPRT is about to break the resistance of cup after a long consolidation. There are two options in front; one ise to break and to continue rising and the other one is forming a handle.
If you find my charts useful, please just leave me a "Like"
thx
